Abstract: A method for quantifying remnant-like lipoprotein cholesterol in a sample simply and accurately without requiring separation operations, and a kit therefor are disclosed. A method for quantifying cholesterol in a remnant-like lipoprotein in a sample containing different lipoproteins including the remnant-like lipoprotein comprises a step (1) of erasing cholesterol in lipoproteins other than the remnant-like lipoprotein; and a step (2) of quantifying cholesterol in the remaining remnant-like lipoprotein. The step (1) is carried out under an action of a cholesterol esterase having a molecular weight of more than 40 kDa and not having a subunit having a molecular weight of not more than 40 kDa; and the step (2) is carried out under an action of a cholesterol esterase having a molecular weight of not more than 40 kDa or a cholesterol esterase having a subunit having a molecular weight of not more than 40 kDa.

Abstract: Provided is an anti-human-norovirus GII antibody which responds to substantially all genotypes of the human noroviruses belonging to GII and which can comprehensively detect such human noroviruses GII. The anti-human-norovirus GII antibody that binds to at least one of epitopes which are contained in amino acid regions represented by the following formulas (1) and (2): P-X1-X2-P-G-E??(1) X3-X4-X5-F-Y-X6-L-X7-P-X8??(2) (wherein, X1 represents L, V, N, T, S, M, or R; X2 represents F, Y, or M; X3 represents V or G; X4 represents N or S; X5 represents Q, P, or S; X6 represents S, T, or I; X7 represents A or S; and X8 represents M or V), and of an epitope formed of amino acid 483 of the amino acid sequence represented by SEQ ID NO: 1, or an epitope formed of an amino acid corresponding to amino acid 483, the regions and the amino acids being present in the P domain of a capsid structural protein of a human norovirus GII.

Abstract: The present invention provides an antibody-immobilized carrier that can be used in antibody screening, a method of producing the antibody-immobilized carrier, and use of the antibody-immobilized carrier. Efficient antibody screening can be carried out particularly by an antibody-immobilized carrier including two or more antibody immobilized regions onto each of which a heavy-chain low-molecular-weight antibody and a light-chain low-molecular-weight antibody are separately immobilized, the two or more antibody immobilized regions each being included in an independent manner, the heavy-chain low-molecular-weight antibody including a heavy-chain variable region, the light-chain low-molecular-weight antibody including a light-chain variable region, the heavy-chain low-molecular-weight antibody and the light-chain low-molecular-weight antibody each being derived from an antibody recognizing a different antigen.

Abstract: A method for fractional measurement of small, dense LDL, which is adaptable for an autoanalyzer, and a reagent for measurement, are provided, making it possible to conduct rapid and convenient analysis with good sensitivity without pretreatment of a specimen. The method for quantitatively determining small, dense LDL cholesterol in a sample comprises the steps of: (1) eliminating cholesterol in LDL other than small, dense LDL in the presence of phospholipase; and (2) quantitatively determining cholesterol in lipoproteins remaining in step (1) above.

Abstract: A method for specifically quantifying HDL cholesterol in which cholesterol in lipoproteins other than HDL is erased in the first step, and HDL cholesterol is specifically quantified in the second step, by which accurate values can be obtained even in measurements of abnormal samples such as disorder of lipid metabolism and lipoprotein abnormality, is disclosed.

Abstract: The present invention aims to provide a method which enables efficient removal of impurities such as the host proteins from an influenza virus culture liquid by a simple operation, allowing separation and purification of an influenza virus antigen. The method of the present invention for producing a purified influenza virus antigen comprises the step of treating a sample containing an influenza virus with a surfactant, the step of bringing the sample after the treatment into contact with hydroxyapatite in the presence of the surfactant, and the step of recovering a hydroxyapatite-non-adsorbed fraction.

Abstract: This invention provides a method for measuring human megalin that can be performed in a simpler manner within a shorter period of time than is possible with conventional techniques, and that can also quantify human megalin. This invention also provides a method that enables diagnosis of functional diseases, which are specific to cells, tissues, or organs, in a site-directed manner at an early stage. Measurement of human megalin enables detection of a disease in an organ in which megalin expression is observed.

Abstract: A rapid and convenient method capable of performing fractional measurement of small, dense LDLs without pretreatment of a specimen, which is adaptable for an autoanalyzer, is provided. A method for quantitatively determining small, dense LDL cholesterol is provided, which comprises adding enzymes for cholesterol measurement to a test sample in the presence of a polyoxyethylene-polyoxypropylene copolymer or a derivative thereof, causing the polyoxyethylene-polyoxypropylene copolymer or the derivative thereof to selectively act on small, dense LDLs among lipoproteins, and then measuring the amount of cholesterol generated.

Abstract: Provided is a test method for acute kidney injury, including detecting urinary podocalyxin. According to the test method, a subject to be tested who has a higher value for the urinary podocalyxin than a reference value can be assessed to have acute kidney injury. Further, as compared to a conventional method, the test method allows acute kidney injury to be assessed accurately and non-invasively, which allows a physical burden on a patient to be reduced. Thus, the test method is useful.

Abstract: This invention provides a diagnostic kit and a diagnostic marker used for diagnosing a renal disease. This invention also provides a method for detecting a renal disease comprising measuring at least one type of human megalin existing in urine selected from among full-length human megalin and human megalin fragments of (i) to (iii): (i) full-length human megalin; (ii) a human megalin endodomain fragment lacking a human megalin ectodomain; and (iii) a human megalin ectodomain fragment lacking a human megalin endodomain.

Abstract: Disclosed is a method for quantifying HDL2 cholesterol in a test sample without requiring laborious operations. The method for quantifying cholesterol comprises allowing phospholipase to act on HDL to quantify cholesterol. Also disclosed is a method comprising: a first step of transferring cholesterols other than high-density lipoproteins in a test sample to the outside of the reaction system; and a second step of quantifying high-density lipoprotein 2 cholesterol among the high-density lipoproteins remaining in the reaction system; wherein, by performing the second step by the above method, high-density lipoprotein 2 cholesterol in the test sample can be quantified.

Abstract: This invention provides a simple means for detecting a renal disorder, a diagnostic marker for a renal disorder that enables prognostic prediction of a renal disorder (e.g., diabetic nephropathy and IgA nephropathy) and evaluation of the degree of nephropathy at the phase of stage-II diabetic nephropathy by measuring the megalin level in urine associated with a renal disorder used for the detection means, and use of such marker. The invention also provides the use of human megalin obtained from the urine sample of a subject as a marker for detecting a renal disorder.

Abstract: A latex agglutination method by which the measurement range is extended and the sensitivity of the measurement in the low concentration range is increased, is disclosed. The method for measuring a test antigen by latex agglutination uses two types of large and small particles, having different average particle sizes. Each latex particle is sensitized with an antibody which undergoes antigen-antibody reaction with the test antigen. The purity of the antibody immobilized on the latex particles is within a specific range. The ratio of the amount of the antibody immobilized per one small latex particle to the amount of the antibody immobilized per one large latex particle; the average particle size of the large latex particles; the average particle size of the small latex particles; the concentration of the large sensitized latex particles in the antigen-antibody reaction system; and the concentration of the small sensitized latex particles in the reaction system are within a specific range.

Abstract: A method for quantifying remnant-like lipoprotein cholesterol in a sample simply and accurately without requiring separation operations, and a kit therefor are disclosed. A method for quantifying cholesterol in a remnant-like lipoprotein in a sample containing different lipoproteins including the remnant-like lipoprotein comprises a step (1) of erasing cholesterol in lipoproteins other than the remnant-like lipoprotein; and a step (2) of quantifying cholesterol in the remaining remnant-like lipoprotein. The step (1) is carried out under an action of a cholesterol esterase having a molecular weight of more than 40 kDa and not having a subunit having a molecular weight of not more than 40 kDa; and the step (2) is carried out under an action of a cholesterol esterase having a molecular weight of not more than 40 kDa or a cholesterol esterase having a subunit having a molecular weight of not more than 40 kDa.

Abstract: Disclosed is an agent for inhibiting decrease in measured values in immunoassays, which may reduce the influences by interfering substances in a test sample so as to promote the accuracy of the immunoassays, as well as an immunoassay and a reagent for immunoassays using the same, with which the decrease in the measured values due to the interfering substances is reduced. The agent for inhibiting decrease in measured values in immunoassays, caused by interfering substances, is an ionic surfactant having a molecular weight of 1000 to 100,000, the agent being a polymer in which a hydrophobic cyclic monomer(s) having an ionic functional group(s) is(are) polymerized.

Abstract: A method that enables quantification of cholesterol in high-density lipoprotein 3 (HDL3) in a test sample without requiring a laborious operation is disclosed. The method for quantifying cholesterol in HDL3 comprises: Step 1 wherein phospholipase and/or sphingomyelinase is/are allowed to act on a test sample to transfer cholesterol to the outside of the reaction system; and Step 2 wherein cholesterol remaining in the reaction system is quantified. The method enables specific quantification of HDL3 cholesterol in a test sample using an automatic analyzer without requirement of a laborious operation such as ultracentrifugation or pretreatment. Further, quantification of the HDL2 cholesterol level can also be carried out by subtracting the HDL3 cholesterol level from the total HDL cholesterol level obtained by a conventional method for quantifying the total HDL cholesterol in a test sample.

Abstract: A method that enables quantification of cholesterol in high-density lipoprotein 3 (HDL3) in a test sample without requiring a laborious operation is disclosed. The method for quantifying cholesterol in HDL3 comprises reacting, with a test sample, a surfactant that specifically reacts with high-density lipoprotein 3, and quantifying cholesterol. The method enables specific quantification of HDL3 cholesterol in a test sample using an automatic analyzer without requirement of a laborious operation such as ultracentrifugation or pretreatment. Further, quantification of the HDL2 cholesterol level can also be carried out by subtracting the HDL3 cholesterol level from the total HDL cholesterol level obtained by a conventional method for quantifying the total HDL cholesterol in a test sample.

Abstract: A method that enables quantification of cholesterol in high-density lipoprotein 3 (HDL3) in a test sample without requiring a laborious operation is disclosed. The method for quantifying cholesterol in HDL3 comprises: Step 1 wherein a surfactant that reacts with lipoproteins other than high-density lipoprotein 3 is reacted with a test sample to transfer cholesterol to the outside of the reaction system; and Step 2 wherein cholesterol remaining in the reaction system is quantified. The method enables specific quantification of HDL3 cholesterol in a test sample using an automatic analyzer without requirement of a laborious operation such as ultracentrifugation or pretreatment. Further, quantification of the HDL2 cholesterol level can also be carried out by subtracting the HDL3 cholesterol level from the total HDL cholesterol level obtained by a conventional method for quantifying the total HDL cholesterol in a test sample.

Abstract: A method for fractional measurement of small, dense LDL, which is adaptable for an autoanalyzer, and a reagent for measurement, are provided, making it possible to conduct rapid and convenient analysis with good sensitivity without pretreatment of a specimen. The method for quantitatively determining small, dense LDL cholesterol in a sample comprises the steps of: (1) eliminating cholesterol in LDL other than small, dense LDL in the presence of phospholipase; and (2) quantitatively determining cholesterol in lipoproteins remaining in step (1) above.

Abstract: This invention provides a immunochromatography detection device that can detect PBP2? produced specifically by a bacterium of multidrug-resistant staphylococcus with high sensitivity in a simple and rapid manner via immunochromatography detection to determine infection with multidrug-resistant staphylococcus, a diagnostic method using such detection device, and a diagnostic kit comprising such detection device.